[go: up one dir, main page]

WO2008124085A3 - Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 - Google Patents

Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 Download PDF

Info

Publication number
WO2008124085A3
WO2008124085A3 PCT/US2008/004434 US2008004434W WO2008124085A3 WO 2008124085 A3 WO2008124085 A3 WO 2008124085A3 US 2008004434 W US2008004434 W US 2008004434W WO 2008124085 A3 WO2008124085 A3 WO 2008124085A3
Authority
WO
WIPO (PCT)
Prior art keywords
jak
mek
formula
compound
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/004434
Other languages
English (en)
Other versions
WO2008124085A2 (fr
Inventor
Peter Lamb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of WO2008124085A2 publication Critical patent/WO2008124085A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008124085A3 publication Critical patent/WO2008124085A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode destinée au traitement d'une maladie chez un mammifère, consistant à lui administrer une dose thérapeutique d'un composé à base de MEK représenté par la formule générale I(M), ou une composition pharmaceutique comprenant une dose thérapeutique d'un composé à base de MEK représenté par la formule générale I(M) et un excipient de qualité pharmaceutique, conjointement avec une dose thérapeutique d'un composé à base de JAK-2 représenté par la formule générale I(J), ou une composition pharmaceutique comprenant une dose thérapeutique d'un composé à base de JAK-2 représenté par la formule générale I(J) et un excipient de qualité pharmaceutique, le composé à base de MEK représenté par la formule générale I(M) et le composé à base de JAK-2 représenté par la formule générale I(J) étant définis dans la description de la présente demande.
PCT/US2008/004434 2007-04-03 2008-04-03 Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 Ceased WO2008124085A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92187807P 2007-04-03 2007-04-03
US60/921,878 2007-04-03

Publications (2)

Publication Number Publication Date
WO2008124085A2 WO2008124085A2 (fr) 2008-10-16
WO2008124085A3 true WO2008124085A3 (fr) 2010-04-15

Family

ID=39722502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004434 Ceased WO2008124085A2 (fr) 2007-04-03 2008-04-03 Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2

Country Status (1)

Country Link
WO (1) WO2008124085A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9290468B2 (en) 2012-01-17 2016-03-22 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2200436B1 (fr) 2007-09-04 2015-01-21 The Scripps Research Institute Pyrimidinyl-amines substituées en tant qu'inhibiteurs de la protéine kinase
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CA2697399C (fr) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aryl-x-phenyl)-1h-pyridine-2-ones 1,3-disubstituees
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (fr) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Dérivés d'indole et de benzoxazine comme modulateurs des récepteurs métabotropiques au glutamate
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2528948T3 (es) 2009-09-21 2015-02-13 Chemocentryx, Inc. Derivados de pirrolidinona carboxamida como moduladores de quemerina-R (ChemR23)
MX2012013274A (es) 2010-05-21 2013-05-28 Chemilia Ab Novedosos derivados de la pirimidina.
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
CN102718750B (zh) * 2011-03-31 2015-03-11 中国人民解放军军事医学科学院毒物药物研究所 含吖啶环的氨基吡啶类衍生物及其用途
BR112013025387B1 (pt) * 2011-04-01 2021-07-27 University Of Utah Research Foundation Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
AU2014236820B2 (en) 2013-03-14 2018-08-02 Sumitomo Pharma Oncology, Inc. JAK2 and ALK2 inhibitors and methods for their use
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
IL291017B2 (en) 2015-10-21 2023-11-01 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
JP6740452B2 (ja) 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
CN106866624B (zh) * 2017-02-27 2017-12-26 济宁医学院 一种卡比替尼的化学合成方法
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019008507A1 (fr) * 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited Dérivés de 2-(4-chlorophénoxy)-n-((1-(2-(4-chlorophénoxy)éthynazétidine-3-yl)méthyl)acétamide et composés apparentés servant d'inhibiteurs d'atf4 pour le traitement du cancer et d'autres maladies
SI3658552T1 (sl) 2017-07-28 2023-11-30 Yuhan Corporation Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
WO2019195753A1 (fr) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Inhibiteurs de kinases axl et leur utilisation
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN111766313B (zh) * 2020-06-04 2022-07-01 京博农化科技有限公司 一种氯吲哚酰肼含量分析方法
US20230080054A1 (en) * 2021-01-22 2023-03-16 Ildong Pharmaceutical Co., Ltd. Inhibitors of anoctamin 6 protein and uses thereof
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN113603677B (zh) * 2021-08-06 2022-06-14 嘉兴特科罗生物科技有限公司 一种具有高口服生物利用度的jak抑制剂
CN113735859A (zh) * 2021-08-12 2021-12-03 安徽医科大学 一种激酶抑制剂
CA3256792A1 (fr) * 2022-04-29 2023-11-02 Beigene , Ltd. Composés 6-(pyrimidin-4-yl) quinoléiques substitués utilisés comme inhibiteurs de kinase dépendante des cyclines
WO2024088323A1 (fr) * 2022-10-27 2024-05-02 Beigene, Ltd. Composés de 6-(pyrimidin-4-yl)quinoléine substituée utilisés en tant qu'inhibiteurs de kinase dépendante des cyclines
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057022A2 (fr) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions de pyrazole utiles comme inhibiteurs de erk
WO2002044166A1 (fr) * 2000-11-02 2002-06-06 Astrazeneca Ab Quinolines substituees comme agents antitumoraux
WO2003015689A2 (fr) * 2001-08-08 2003-02-27 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Composition pharmaceutique de prevention et/ou de traitement de maladies virales
WO2004113347A1 (fr) * 2003-06-20 2004-12-29 Celltech R & D Limited Derives de thienopyridone en tant qu'inhibiteurs de kinase
WO2006017443A2 (fr) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
WO2006045514A1 (fr) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. Derives de 3-arylamino pyridine
WO2006061712A2 (fr) * 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
WO2007044515A1 (fr) * 2005-10-07 2007-04-19 Exelixis, Inc. Inhibiteurs de mek et procedes pour les utiliser
WO2008021389A2 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procédés d'utilisation de modulateurs pi3k etmek

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057022A2 (fr) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions de pyrazole utiles comme inhibiteurs de erk
WO2002044166A1 (fr) * 2000-11-02 2002-06-06 Astrazeneca Ab Quinolines substituees comme agents antitumoraux
WO2003015689A2 (fr) * 2001-08-08 2003-02-27 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Composition pharmaceutique de prevention et/ou de traitement de maladies virales
WO2004113347A1 (fr) * 2003-06-20 2004-12-29 Celltech R & D Limited Derives de thienopyridone en tant qu'inhibiteurs de kinase
WO2006017443A2 (fr) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
WO2006045514A1 (fr) * 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. Derives de 3-arylamino pyridine
WO2006061712A2 (fr) * 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
WO2007044515A1 (fr) * 2005-10-07 2007-04-19 Exelixis, Inc. Inhibiteurs de mek et procedes pour les utiliser
WO2008021389A2 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procédés d'utilisation de modulateurs pi3k etmek

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERTRAND F E ET AL: "Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support", January 2005, LEUKEMIA 200501 GB, VOL. 19, NR. 1, PAGE(S) 98 - 102, ISSN: 0887-6924, XP002559583 *
LO RICO K H ET AL: "Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism.", 26 December 2003, JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 278, NR. 52, PAGE(S) 52154-52165, ISSN: 0021-9258, XP002559584 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9290468B2 (en) 2012-01-17 2016-03-22 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof
US9937158B2 (en) 2012-01-17 2018-04-10 Shanghai Kechow Pharma, Inc. Benzoheterocyclic compounds and use thereof

Also Published As

Publication number Publication date
WO2008124085A2 (fr) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008124085A3 (fr) Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2008075068A3 (fr) Nouveaux composés
WO2007100895A3 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
WO2007136759A3 (fr) Procédé de traitement et de prévention de troubles oculaires
WO2010093849A3 (fr) Dérivés de la phénylalanine-amide utiles pour le traitement de maladies et états liés à l'insuline
EP2512479A4 (fr) Méthodes et compositions destinées au traitement de maladies vasculaires périphériques
WO2007149797A3 (fr) Utilisation de composés organiques
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2008127594A3 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
WO2009156735A3 (fr) Nouveaux agents thérapeutiques
WO2008070268A3 (fr) Compositions pharmaceutiques
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
WO2009002808A3 (fr) Composés de quinazolinone et leurs méthodes d'utilisation
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2010044585A3 (fr) Composes de piperidine, composition pharmaceutique les contenant et utilisation associee
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
WO2007133944A3 (fr) Administration topique d'acyclovir
WO2007024843A3 (fr) Inhibiteurs de pyrimidinyl-pyrazole d'aurora kinases
TNSN08506A1 (en) Substituted carboxamides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742584

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008742584

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE